Thalidomide in multiple myeloma: state of art

Next Generation Flow and Next Generation Sequencing for Measurable Residual Disease Assessment in Multiple Myeloma Patients: A Real-Life Italian Multicenter Harmonization Experience.

Cancer medicine·2026

REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trials.

Haematologica·2026

Addressing unmet needs in relapsed/refractory multiple myeloma: an Italian Delphi consensus on current challenges and emerging therapies.

Frontiers in oncology·2026

Real-world effectiveness and safety of belantamab mafodotin monotherapy in patients with relapsed/ refractory multiple myeloma treated in Europe.

Haematologica·2026

Daratumumab-based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study.

HemaSphere·2026

AI-derived five-gene signature predicts risk in multiple myeloma under bortezomib-based therapy.

Scientific reports·2025

Genetic thrombophilia in cancer-associated thrombosis: the fly plowing with the ox or an old player's new role?

Haematologica·2026

From prognostic discrimination to clinical utility in high-risk myeloma. Comment on: "Risk factors and their contributions to prognosis in multiple myeloma".

Haematologica·2026

Learning from relapse: how MajesTEC-1 immune profiling points the way to next-generation bispecific strategies.

Haematologica·2026

Making remissions last: the promise of maintenance in primary central nervous system lymphoma.

Haematologica·2026

Venetoclax combined with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia: outcomes and risk stratification.

Haematologica·2026

The many faces (and phenotypes) of BCR::ABL1-driven acute leukemia.

Haematologica·2026

Myotonic dystrophy type 1 - updates on mechanisms of multisystemic manifestations, genetically targeted therapeutics, and preparing for a postapproval world.

Current opinion in neurology·2026

Immunotherapeutic efficacy of transdermal delivery of anti-CD3 antibody-conjugated magnetic nanoparticles using a hyaluronic acid-based dissolving microneedle patch.

Drug delivery and translational research·2026

Innovations in transcatheter interventions for hypoplastic left heart syndrome and borderline left heart structures from fetal to neonatal life: current evidence and systematic review of recent advances (2016-2025).

European journal of pediatrics·2026

Viewpoint on Multisensory Technologies.

Multisensory research·2026

CRISPR/Cas12a-based tag-free fluorescent biosensor using G-quadruplex specific thioflavin T for detection of oncogenic microRNAs.

Methods (San Diego, Calif.)·2026

HBVZ10 Exhibits Robust In Vivo Potency and Synergizes with Entecavir to Drive Efficient cccDNA Elimination and HBsAg Seroclearance.

Antiviral research·2026

Related Experiment Videos

Thalidomide in multiple myeloma: state of art

Related Concept Videos

Next Generation Flow and Next Generation Sequencing for Measurable Residual Disease Assessment in Multiple Myeloma Patients: A Real-Life Italian Multicenter Harmonization Experience.

REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trials.

Addressing unmet needs in relapsed/refractory multiple myeloma: an Italian Delphi consensus on current challenges and emerging therapies.

Real-world effectiveness and safety of belantamab mafodotin monotherapy in patients with relapsed/ refractory multiple myeloma treated in Europe.

Daratumumab-based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study.

AI-derived five-gene signature predicts risk in multiple myeloma under bortezomib-based therapy.

Genetic thrombophilia in cancer-associated thrombosis: the fly plowing with the ox or an old player's new role?

From prognostic discrimination to clinical utility in high-risk myeloma. Comment on: "Risk factors and their contributions to prognosis in multiple myeloma".

Learning from relapse: how MajesTEC-1 immune profiling points the way to next-generation bispecific strategies.

Making remissions last: the promise of maintenance in primary central nervous system lymphoma.

Venetoclax combined with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia: outcomes and risk stratification.

The many faces (and phenotypes) of BCR::ABL1-driven acute leukemia.

Myotonic dystrophy type 1 - updates on mechanisms of multisystemic manifestations, genetically targeted therapeutics, and preparing for a postapproval world.

Immunotherapeutic efficacy of transdermal delivery of anti-CD3 antibody-conjugated magnetic nanoparticles using a hyaluronic acid-based dissolving microneedle patch.

Innovations in transcatheter interventions for hypoplastic left heart syndrome and borderline left heart structures from fetal to neonatal life: current evidence and systematic review of recent advances (2016-2025).

Viewpoint on Multisensory Technologies.

CRISPR/Cas12a-based tag-free fluorescent biosensor using G-quadruplex specific thioflavin T for detection of oncogenic microRNAs.

HBVZ10 Exhibits Robust In Vivo Potency and Synergizes with Entecavir to Drive Efficient cccDNA Elimination and HBsAg Seroclearance.

Related Experiment Videos

Thalidomide in multiple myeloma: state of art

Related Concept Videos

Related Articles